McDermott Advises Aelis Farma on an Exclusive Sub-License and Co-Development Option Contract with Indivior

Overview


Aelis Farma, a biotechnology company specializing in the treatment of brain diseases, has finalized an exclusive sub-license and co-development option contract with laboratory Indivior Plc in order to treat disorders related to the use of cannabis, including cannabis-induced psychosis.

The McDermott team that advised Aelis Farma included Emmanuelle Trombe, Gary Howes and Edouard Becker.

For the full media coverage (in French), please click here.